6.1.2 Concurrent opioid use or MOUDs
The use of psychedelics as an add-on to, or concurrently with
medications that work at the MOR may have unintended effects. Being
prepared to prevent or mitigate possible withdrawal states should be
taken into consideration. The impact of possible withdrawal states on
the subjective psychedelic experience should also be considered and
timing of dosing of any concurrent MOR should be thoughtfully
considered. For many studies of ibogaine and noribogaine, MOUD is
commonly switched to shorter-acting medications such as
controlled-release oral morphine products or other short-acting MOR
agonists.125 There are also possibly important safety
concerns related to concurrent use of opioids and some psychedelics,
which are reviewed below.